Bears REASONS TO SELL
December 06, 2013
(Jutia Group, 12/6/13)
[at Motley Fool] - With Gilead (GILD), Johnson and Johnson (JNJ), AbbVie (ABBV), Bristol-Myers (BMY), and Merck (MRK)...(read more)
(Jutia Group, 12/2/13)
[at Forbes] - According to GuruFocus Insider Data, the largest insider sells during the past week were: Google Inc, Freeport-McMoRan Copper & Gold, Gilead Sciences...(read more)
(Stock Blog Hub, 8/4/13)
Gilead Sciences Inc. (GILD) recently announced that its Marketing Authorisation Application (MAA) for HCV candidate sofosbuvir (formerly GS-7977), submitted to the European...(read more)
Gilead Sciences (GILD) Company Overview
Gilead Sciences (NYSE: GILD) is a biopharmaceutical company that specializes in the development and commercialization of drugs for the treatment of HIV infection, hepatitis B infection (HBV), cystic fibrosis, fungal infections, and influenza A and B. The company currently produces a market-leading HIV drug portfolio as well as other drugs, which face strong competition from drug-makers such as GlaxoSmithKline (GSK), Novartis AG (NVS), Merck (MRK), Enzon Pharmaceuticals (ENZN), and Bristol-Myers Squibb Company (BMY).In 2010, Gilead generated $7.95 billion in revenues and net earnings of $2.9 billion.
Gilead's profitability can be potentially affected by various factors, including legislative and regulatory changes in federal and private insurance coverage of its drug products, competition from the development of generic drug substitutes, supply shortages of active ingredients in its drugs, the success of clinical trials of newly-developed drugs, and changes in FDA regulations.(Read more at Wikinvest )
What's in this GILD analysis on Wikinvest...